Entrada Therapeutics (TRDA) Equity Average (2020 - 2026)

Entrada Therapeutics' Equity Average history runs 7 years deep, the most recent figure standing at $288.5 million for Q1 2026.

• In Q1 2026, Equity Average fell 31.79% year-over-year to $288.5 million; the TTM figure through Mar 2026 stood at $288.5 million (down 31.79% YoY), while the FY2025 annual figure was $367.4 million, up 9.5% from the prior year.
• Equity Average was $288.5 million for Q1 2026 at Entrada Therapeutics, down from $323.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $426.2 million in Q3 2024 to a low of $218.3 million in Q2 2023.
• Historically, Equity Average has averaged $304.9 million across 5 years, with a median of $288.1 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Equity Average surged 731.98% in 2022, then tumbled 31.79% in 2026.
• A 5-year view of Equity Average shows it stood at $222.9 million in 2022, then climbed by 9.7% to $244.5 million in 2023, then surged by 74.05% to $425.6 million in 2024, then decreased by 24.0% to $323.4 million in 2025, then retreated by 10.8% to $288.5 million in 2026.
• The last three Equity Average figures came in at $288.5 million (Q1 2026), $323.4 million (Q4 2025), and $360.1 million (Q3 2025), per Business Quant data.